Monday 8th July 201913:15–14:30

Room 212–213, Melbourne Convention and Exhibition Centre (MCEC), Melbourne, Australia

Co-chairs: John Rasko (Australia), Ian Winburn (Pfizer)

Pfizer Satellite Symposium at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

Transformative science in an era of comprehensive care: from lab to life

Federation Square, Melbourne

PP-BEN-GLB-0101-05/19

Date of preparation: May 2019

Pfizer Australia Pty Ltd, Sydney, Australia

This symposium is initiated and funded by Pfizer

Co-chairs: John Rasko (Australia), Ian Winburn (Pfizer)

13:15 Welcome and introduction Co-chairs

13:25 Transformational science in an era of comprehensive care: Mike Laffan (UK) understanding alternative targets of coagulation

13:45 Transformational science in an era of comprehensive care: Barbara Konkle (USA) gene therapy – past, present and future

14:05 Comprehensive care in an era of transformational therapy: Huyen Tran (Australia) practical considerations

14:20 Panel discussion All

14:30 Meeting summary and close Co-chairs

Agenda

PP-BEN-GLB-0101-05/19

Date of preparation: May 2019

Pfizer Australia Pty Ltd, Sydney, Australia

Dear Delegates,

It is with great pleasure that we invite you to join us for the Pfizer-sponsored symposium taking place at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2019.

Transformative science in an era of comprehensive care: from lab to life

In this era of transformative science, the field of haemophilia is pioneering advanced, targeted therapeutic approaches for patients. However, questions remain around the potential impact and clinical considerations these advances may bring, including sustainability, immunogenicity, patient selection and organisation of care.

Through a shared understanding of the science underpinning alternative approaches to treatment, focusing on non-factor-based targets and gene therapy, this symposium will explore the scientific rationale behind these approaches.

Additionally, by reviewing the evolution of comprehensive care models, we will explore the potential impact of these advances on comprehensive care. Finally, we will look at the importance of exploring evolving models of care in adapting to the rapidly changing haemophilia landscape.

We look forward to welcoming you to this stimulating and educational symposium.

John Rasko Ian Winburn Head of Department, Cell & Molecular Global Medical Team Lead, Haemophilia, Therapies, Royal Prince Alfred Hospital, Pfizer New South Wales, Australia

This symposium is initiated and funded by Pfizer